Genus Share News (GNS)

Shares in Sinclair Pharma continue to fall following yesterday's announcement that the pharma company was ending its distribution agreement for Decapinol mouth rinse with Orapharma Inc. Orapharma, a subsidiary of Johnson & Johnson, held US rights to the product for the dental professionals market. The termination of the deal will lead to a loss of short-term milestone payments. Sinclair is confident that it can secure a more wide ranging licence to Decapinol and this will have long-term benefits for shareholders. Sinclair intends to include the over the counter market in the next deal. Sinclair has negotiated new debt facilities of £9m and is raising £18m from a share placing. The cash will finance the acquisition of products from Solvay Pharmaceuticals.In contrast, shares in animal genetics company Genus bounced back after its former broker Panmure Gordon said yesterday's share price fall was a buying opportunity. Genus warned that trading was weaker than expected and the US market was still deteriorating. Panmure has cut its full year profit forecast from £33m to £30m. However, it has maintained its share price target of 700p. FTSE TechMARK - RisersGenus (GNS) 607.50p +6.58%RM Group (RM.) 150.00p +2.39%Kewill (KWL) 99.00p +2.06%Emblaze (BLZ) 51.00p +2.00%Phoenix IT Group (PNX) 226.50p +1.80%Skyepharma (SKP) 90.00p +1.69%Kofax (KFX) 186.00p +1.64%NCC Group (NCC) 399.50p +1.52%NXT (NTX) 17.75p +1.43%BAE Systems (BA.) 320.30p +1.42%FTSE TechMARK - FallersSepura (SEPU) 39.00p -4.88%Filtronic (FTC) 34.00p -3.55%Wolfson Microelectronics (WLF) 119.00p -3.45%Sinclair Pharma (SPH) 32.75p -2.96%Optos (OPTS) 89.00p -2.73%Autonomy Corporation (AU.) 1,406.00p -2.70%BATM Advanced (BVC) 50.50p -2.42%Innovation Group (TIG) 12.25p -2.00%Ark Therapeutics (AKT) 37.75p -1.95%Consort Medical (CSRT) 396.00p -1.86%